Stock Mover of the Day: Is Selling Amicus Therapeutics, Inc. Here a Winning Strategy?

Stock Mover of the Day: Is Selling Amicus Therapeutics, Inc. Here a Winning Strategy?

The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a huge mover today! About 5.70 million shares traded hands or 113.48% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has declined 16.32% since April 27, 2016 and is downtrending. It has underperformed by 21.55% the S&P500.
The move comes after 5 months negative chart setup for the $670.41 million company. It was reported on Nov, 30 by We have $5.48 PT which if reached, will make NASDAQ:FOLD worth $60.34 million less.

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on February, 24. They expect $-0.31 earnings per share, up 11.43% or $0.04 from last year’s $-0.35 per share. After $-0.33 actual earnings per share reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -6.06% EPS growth.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Out of 7 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Amicus Therapeutics has been the topic of 11 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The rating was initiated by Bank of America with “Buy” on Wednesday, May 18. The rating was maintained by Leerink Swann with “Outperform” on Monday, October 5. The company was maintained on Tuesday, September 1 by Cowen & Co. The rating was maintained by Leerink Swann with “Buy” on Monday, August 31. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Buy” rating by Zacks on Tuesday, August 18. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Neutral” rating by Goldman Sachs on Wednesday, March 30. Chardan Capital Markets upgraded Amicus Therapeutics, Inc. (NASDAQ:FOLD) rating on Monday, October 5. Chardan Capital Markets has “Buy” rating and $8 price target. The firm has “Buy” rating by Janney Capital given on Tuesday, March 8. JP Morgan maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) rating on Tuesday, September 8. JP Morgan has “Overweight” rating and $28 price target. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Neutral” rating given on Thursday, April 14 by Robert W. Baird.

According to Zacks Investment Research, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.”

Insitutional Activity: The institutional sentiment decreased to 1.49 in Q2 2016. Its down 0.15, from 1.64 in 2016Q1. The ratio turned negative, as 20 funds sold all Amicus Therapeutics, Inc. shares owned while 25 reduced positions. 22 funds bought stakes while 52 increased positions. They now own 136.20 million shares or 2.45% more from 132.95 million shares in 2016Q1.
Us Retail Bank De owns 4,805 shares or 0% of their US portfolio. Moreover, Artal Group Sa has 0.14% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 1.25 million shares. Berson And Corrado Inv Advsr Llc has invested 0.04% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Deutsche Bancorporation Ag holds 0% or 857,628 shares in its portfolio. Teachers Retirement Systems Of The State Of Kentucky accumulated 55,590 shares or 0% of the stock. Blackrock Invest Management Limited Liability Company has 0% invested in the company for 472,055 shares. Pacad Investment Ltd reported 78,286 shares or 0.06% of all its holdings. Tiaa Cref Management Ltd Com last reported 0% of its portfolio in the stock. Sabby Mngmt holds 0.04% or 125,912 shares in its portfolio. Stevens Capital Limited Partnership last reported 16,824 shares in the company. Bnp Paribas Arbitrage has invested 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). California Public Employees Retirement accumulated 0% or 276,800 shares. Emerald Mutual Fund Advisers Trust last reported 1.10 million shares in the company. D E Shaw & Inc last reported 2.78 million shares in the company. Savings Bank Of America De, a North Carolina-based fund reported 62,750 shares.

Insider Transactions: Since June 2, 2016, the stock had 0 insider buys, and 9 insider sales for $8.65 million net activity. The insider Do Hung sold $175,000. Baird William D III sold $164,075 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Tuesday, September 20. $115,050 worth of shares were bought by Rosenberg Ellen on Thursday, June 2. 66,300 shares were bought by Redmile Group – LLC, worth $477,360. Barth Jay sold 10,458 shares worth $73,206. $7.49M worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares were sold by PERCEPTIVE ADVISORS LLC. On Wednesday, November 9 the insider Quimi Daphne sold $68,368.

More news for Amicus Therapeutics, Inc. (NASDAQ:FOLD) were recently published by:, which released: “Analyst Downgrades: Shoe Carnival, Inc., Amicus Therapeutics, Inc., and …” on November 29, 2016.‘s article titled: “Here’s Why Amicus Therapeutics, Inc. Soared As Much As 20% Despite an Earnings …” and published on November 07, 2016 is yet another important article.

FOLD Company Profile

Amicus Therapeutics, Inc., incorporated on February 4, 2002, is a biopharmaceutical company. The Firm is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. The Company’s lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). The Firm has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. The Firm is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa (EB). It has also initiated a clinical study in patients with Pompe disease, another LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase (rhGAA) enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with a pharmacological chaperone, AT2221, to improve activity and stability.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment